1. Guariguata L, Whiting DR, Hambleton I, Beagley J,
Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and
projections for 2035.Diabetes Res. Clin. Pract.2014; 103: 137–149.
2.
International
Diabetes Federation.Brussels: 2013. International Diabetes Federation IDF
Diabetes Atlas.
3. Nathan D.M. Long-Term Complications of
Diabetes-Mellitus.N. Engl. J. Med.1993; 328:1676–1685.
4.
Bailey C, Day C.
Metformin: its botanical background.Pract. Diabetes Int. 2004; 21:
115–117.
5.
Watanabe C.K. Studies
in the metabolic changes induced by administration of guanidine bases.J. Biol. Chem.1918; 33:253–265.I.
Influence of injected guanidine
hydrochloride upon blood sugar content.
6. Hundal RS, Krssak M, Dufour S, Laurent D, Lebon V,
Chandramouli V, Inzucchi SE, Schumann WC, Petersen KF, Landau BR, Shulman GI.
Mechanism by which metformin reduces glucose production in type2
diabetes.Diabetes.2000; 49: 2063–2069.
7. Shu Y, Sheardown SA, Brown C, Owen RP, Zhang S, Castro
RA, Ianculescu AG, Yue L, Lo JC, Burchard
EG, Brett CM, Giacomini KM.
Effect of genetic variation in the organic cation transporter 1 (OCT1) on
metformin action.J. Clin. Invest.2007; 117:1422–1431.
8. Owen M.R., Doran E., Halestrap A.P. Evidence that
metformin exerts its anti-diabetic effects through inhibition of complex 1 of
the mitochondrial respiratory chain.Biochem. J. 2000; 348:607–614.
9. Viollet B., Guigas B., Sanz Garcia N., Leclerc J.,
Foretz M., Andreelli F. Cellular and molecular mechanisms of metformin: an
overview.Clin. Sci.2012; 122:253–270.
10. El-Mir M-Y, Nogueira V, Fontaine E, Avéret N, Rigoulet
M, Leverve X. Dimethylbiguanide inhibits cell respiration via an indirect
effect targeted on the respiratory chain complex I.J. Biol.
Chem.2000; 275: 223–228.
11. Stephenne X., Foretz M., Taleux N., van der Zon G.C.,
Sokal E., Hue L., Viollet B., Guigas B. Metformin activates AMP-activated
protein kinase in primary human hepatocytes by decreasing cellular energy
status.Diabetologia.2011; 54: 3101–3110.
12. NelsonDL, Cox MM. Lehninger Principles of
Biochemistry. 2005. Four edition pp 690- 719 WH. Freedman & Co. New York.
13. Logie L, Harthill J, Patel K, Bacon S, Hamilton
DL, Macrae K, McDougall G, Wang H-H, Xue L, Jiang H, Sakamoto K, Prescott AR, Rena G.
Cellular responses to the metal-binding properties of metformin. Diabetes.
2012; 61: 1423–1433.
14. Repiscak P, Erhardt S,
Rena G, Paterson M.J. Biomolecular mode of action of metformin in relation to its copper binding properties.Biochemistry.2014; 53:787–795.
15. Bridges HR, Jones AJY, Pollak MN, Hirst J. Effects of
metformin and other biguanides on oxidative phosphorylation
in mitochondria.Biochem. J.2014;
462: 475–487.
16. Drahota Z, Palenickova E, Endlicher R, Milerova M,
Brejchova J, Vosahlikova M., Svoboda P, Kazdova L, Kalous M, Cervinkova
Z, Cahova M. Biguanides inhibit complex I, II and IV of
rat liver mitochondria and modify their
functional properties. Physiol. Res.2014; 63: 1–11.
17. Coughlan KA, Valentine RJ, Ruderman NB, Saha AK. AMPK
activation: a therapeutic target for type 2 diabetes? Diabetes Metab Syndr Obes : Targets and Therapy 2014: 7
241–253
18. Steinberg GR, Kemp BE. AMPK in Health and Disease.
Physiol Rev. 2009; 89 :1025–1078.
19. O’Neill HM. AMPK and exercise: glucose uptake and
insulin sensitivity. Diabetes Metab J. 2013; 37:1–21
20. Xiao B, Heath R, Saiu P, et al. Structural basis for
AMP binding to mammalian AMP-activated protein kinase. Nature. 2007; 449: 496–500.
21. Davies SP, Helps NR, Cohen PT, Hardie DG. 5′-AMP
inhibits dephosphorylation, as well as promoting
phosphorylation, of the AMP-activated protein kinase. Studies using
bacterially expressed human protein phosphatase-2C alpha and native bovine
protein phosphatase-2AC. FEBS Lett. 1995; 377: 421–425.
22. Suter M, Riek U, Tuerk R, Schlattner U, Wallimann T,
Neumann D. Dissecting the role of 5′-AMP for allosteric stimulation,
activation, and deactivation of AMP-activated protein kinase. J Biol Chem. 2006; 281: 32207–32216.
23. Gowans GJ, Hawley SA, Ross FA, Hardie DG. AMP is a
true physiological regulator of AMP-activated protein kinase by both
allosteric activation and enhancing net phosphorylation. Cell Metab. 2013; 18: 556–566.
24.
Zhu L., Chen L., Zhou X.M., Zhang Y.Y., Zhang Y.J., Zhao J., Ji S.R., Wu J.W., Wu Y. Structural Insights into the Architecture and Allostery of Full-Length AMP-Activated Protein Kinase.
Structure. 2011; 19: 515-522.
25.
Iseli TJ, Walter M, van Denderen BJ, Katsis F, Witters LA, Kemp BE, Michell BJ, Stapleton D. AMP-activated protein kinase beta subunit tethers
alpha and gamma subunits via its C-terminal sequence (186-270). J Biol Chem. 2005; 280: 13395-400.
26.
McBride A., Ghilagaber S., Nikolaev A., Hardie DG. The Glycogen-Binding Domain on the AMPK β Subunit Allows the Kinase to Act as a Glycogen
Sensor. Cell Metab. 2009; 9: 23–34.
27. Woods A, Johnstone SR, Dickerson K, et al. LKB1 is
the upstream kinase in the AMP-activated protein kinase cascade.
Curr Biol. 2003;13 :2004–2008.
28. Hawley SA, Pan DA, Mustard KJ, Ross L, Bain J, Edelman AM, Frenguelli BG, Hardie DG. Calmodulin-dependent protein kinase
kinase-beta is an alternative upstream kinase for AMP-activated protein
kinase. Cell Metab.
2005; 2: 9–19.
29. Momcilovic M, Hong SP, Carlson M. Mammalian TAK1
activates Snf1 protein kinase in yeast and phosphorylates
AMP-activated protein kinase in vitro. J Biol Chem. 2006; 281: 25336–25343.
30. Hurley RL, Barré LK, Wood SD, et al. Regulation of
AMP-activated protein kinase by multisite phosphorylation in
response to agents that elevate cellular cAMP. J Biol Chem. 2006; 281: 36662–36672.
31. Ning J, Xi G, Clemmons DR. Suppression of AMPK
activation via S485 phosphorylation by IGF-I during hyperglycemia is
mediated by AKT activation in vascular smooth muscle cells.
Endocrinology. 2011; 152: 3143–3154.
32. Hawley SA, Ross FA, Gowans GJ, Tibarewal P, Leslie
NR, Hardie DG. Phosphorylation by Akt within the ST loop of AMPK-α1
downregulates its activation in tumour cells. Biochem J. 2014; 459: 275–287.
33. Munday MR, Campbell DG, Carling D, Hardie DG.
Identification by amino acid sequencing of three major regulatory phosphorylation
sites on rat acetyl- CoA carboxylase. Eur J Biochem. 1988; 175: 331–338.
34. Inoki K, Zhu T, Guan KL. TSC2 mediates cellular
energy response to control cell growth and survival. Cell. 2003; 115: 577–590.
35. Zong H, Ren JM, Young LH, Pypaert M, Mu J, Birnbaum MJ, Shulman GI. AMP kinase is required for mitochondrial biogenesis in skeletal
muscle in response to chronic energy deprivation. Proc Natl Acad Sci U S A. 2002; 99: 15983–15987.
36. Ruderman NB, Carling D, Prentki M, Cacicedo JM. AMPK,
insulin resistance, and the metabolic syndrome. J Clin Invest. 2013; 123: 2764–2772.
37. Srivastava RA, Pinkosky SL, Filippov S, Hanselman JC,
Cramer CT, Newton RS. AMP-activated protein kinase: an emerging
drug target to regulate imbalances in lipid and carbohydrate
metabolism to treat cardio-metabolic diseases. J Lipid Res. 2012; 53: 2490–2514.
38.
Minokoshi Y, Alquier T, Furukawa N, Kim YB, Lee A,
Xue B, Mu J, Foufelle F, Ferré P, Birnbaum MJ, Stuck BJ, Kahn BB.. AMP-kinase
regulates food intake by responding to hormonal and
nutrient signals in the hypothalamus. Nature. 2004; 428: 569–574.
39. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J,
Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE. Role of AMP-activated
protein kinase in mechanism of metformin action. J. Clin.
Invest.2001; 108: 1167–1174.
40. Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N,
Depinho RA, Montminy M, Cantley LC. The kinase LKB1 mediates glucose homeostasis
in liver and therapeutic effects of metformin. Science. 2005; 310:
1642–1646.
41. Foretz M, Hebrard S, Leclerc J, Zarrinpashneh E, Soty
M, Mithieux G, Sakamoto K, Andreelli F, Viollet B. Metformin inhibits hepatic
gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease
in hepatic energy state.J. Clin. Invest.2010; 120: 2355–2369.
42. Fullerton MD, Galic S, Marcinko K, Sikkema S,
Pulinilkunnil T, Chen ZP, O'Neill HM, Ford RJ, Palanivel R, O'Brien M, Hardie DG, Macaulay SL, Schertzer JD, Dyck JR, van Denderen BJ, Kemp BE, Steinberg GR.
Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin-sensitizing effects of metformin.
Nat. Med.2013; 19: 1649–1654.
43.
Kawaguchi T, Osatomi K, Yamashita H, Kabashima T,
Uyeda K. Mechanism for fatty acid
“sparing” effect on glucose-induced transcription: regulation of carbohydrate-responsive
element-binding protein by AMP-activated protein
kinase.J. Biol. Chem. 2002; 277: 3829–3835.
44. Ouyang J., Parakhia R.A., Ochs R.S. Metformin
activates AMP kinase through inhibition of AMP deaminase.J. Biol. Chem.
2011; 286: 1–11.
45.
Meng S, Cao J, He Q, Xiong L, Chang E, Radovick S,
Wondisford FE, He L. Metformin activates AMP-activated protein kinase by
promoting formation of the alphabetagamma heterotrimeric complex.J. Biol.
Chem.2015; 290: 3793–3802.
46. Hawley SA,
Gadalla AE, Olsen GS, Hardie DG. The antidiabetic drug
metformin activates the AMP-activated protein kinase cascade via an adenine
nucleotide-independent mechanism.Diabetes.2002; 51: 2420–2425.
47.
Miller RA, Birnbaum MJ. An energetic tale of
AMPK-independent effects of metformin.J. Clin. Invest.2010; 120:
2267–2270.
48.
McGrane M.M., El-Maghrabi M.R., Pilkis S.J. The
interaction of fructose 2,6- bisphosphate
and AMP with rat hepatic fructose 1,6-bisphosphatase.J. Biol. Chem.1983; 258: 10445–10454.
49. Burgess SC, He T, Yan Z, Lindner J, Sherry AD, Malloy
CR, Browning JD, Magnuson MA.
Cytosolic phosphoenolpyruvate carboxykinase does not solely control the rate of hepatic gluconeogenesis in the
intact mouse liver.Cell Metab.2007; 5: 313–320.
50. Samuel V.T., Beddow S.A., Iwasaki T., Zhang X.M., Chu
X., Still C.D., Gerhard G.S., Shulman G.I. Fasting hyperglycemia is not
associated with increased expression of PEPCK or G6Pc in patients with
Type2 Diabetes.Proc. Natl. Acad. Sci. U.S.A.2009; 106:
12121–12126.
51.
Miller RA, Chu Q, Xie J, Foretz M, Viollet B,
Birnbaum MJ. Biguanides suppress hepatic glucagon signalling by decreasing
production of cyclic AMP.Nature.2013; 494: 256–260.
52. Gelling RW, Du XQ, Dichmann DS, Romer J, Huang H, Cui
L, Obici S, Tang B, Holst JJ,
Fledelius C, Johansen PB, Rossetti L, Jelicks LA, Serup P, Nishimura E, Charron MJ. Lower blood glucose, hyperglucagonemia, and
pancreatic alpha cell hyperplasia in glucagon receptor knockout
mice.Proc. Natl. Acad. Sci. U.S.A.2003; 100: 1438–1443.
53. Pernicova I, Korbonits M. Metformin–mode of action and clinical
implications for diabetes and
cancer.Nat. Rev. Endocrinol.2014; 10: 143–156.
54. Madiraju AK,
Erion DM, Rahimi Y, Zhang X-M, Braddock DT, Albright RA, Prigaro BJ, Wood JL, Bhanot S, MacDonald
MJ, Jurczak MJ, Camporez JP, Lee HY, Cline GW, Samuel VT, Kibbey RG, Shulman GI. Metformin
suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate
dehydrogenase.Nature.2014; 510: 542–546.
55.
Pryor R., Cabreiro F. Repurposing metformin: an old drug with new
tricks in its binding pockets.
Biochem J. 2015; 471: 307–322.
56. Franciosi M, Lucisano G, Lapice E, Strippoli GFM,
Pellegrini F, Nicolucci A. Metformin therapy and risk of cancer in patients
with type2 diabetes: systematic review. PLoS One.2013; 8: 1–12.
57. Coll
T, Rodríguez-Calvo R, Barroso E, Serrano L,
Eyre E,
Palomer X,
Vázquez-Carrera M..
Peroxisome proliferator-activated
receptor (PPAR)β/δ: a new potential therapeutic target for the treatment
of metabolic syndrome. Curr Mol
Pharmacol.2009; 2: 46– 55.
58.
Lee CH, Olson P, Evans RM. Minireview: lipid metabolism,
metabolic diseases, and peroxisome proliferator-activated receptors.Endocrinology.2003; 144: 2201–2207.
59.
Issemann I, Green S. Activation of a member of
the steroid hormone receptor superfamily
by peroxisome proliferators.Nature.1990;
347: 645–650.
60. Feige JN, Gelman L, Michalik L, Desvergne B, Wahli W.
From molecular action to physiological outputs: peroxisome
proliferator-activated receptors are nuclear receptors at the crossroads of key
cellular functions.Prog Lipid
Res.2006; 45: 120–159.
61.
Michalik L, Auwerx J, Berger JP, Chatterjee VK, Glass CK, Gonzalez FJ, Grimaldi PA, Kadowaki T, Lazar MA, O'Rahilly S, Palmer CN, Plutzky J, Reddy JK, Spiegelman BM, Staels B, Wahli W. International union of
pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacological
Reviews. 2006; 58:
726–741.
62. Rosen ED, Walkey CJ,
Puigserver P, Spiegelman BM. Transcriptional regulation of adipogenesis.Genes and Dev.2000; 14:
1293–1307.
63. Berger J, Moller DE. The mechanisms of action of
PPARs.Annu Rev Med.2002;
53: 409–435.
64.
Lemberger T, Desvergne B, Wahli W. Peroxisome
proliferator-activated receptors: a nuclear receptor signaling pathway in lipid
physiology.Annu Rev Cell Dev
Biol.1996; 12: 335–363.
65. Ricote M, Valledor AF,
Glass CK. Decoding transcriptional programs regulated by PPARs and LXRs in the macrophage: effects on lipid
homeostasis, inflammation, and atherosclerosis.Arterioscler Thromb Vasc Biol.2004; 24: 230–239.
66. Hevener
AL, He W, Barak Y, et al. Muscle-specific
Pparg deletion causes insulin resistance.Nat Med. 2003; 9: 1491–1497.
67. Smith U, Gogg S, Johansson A, Olausson T, Rotter V,
Svalstedt B. Thiazolidinediones (PPARγagonists) but not PPARαagonists increase IRS-2 gene expression in
3T3-L1 and human adipocytes.FASEB
Journal. 2001; 15: 215–220.
68. Arner P. The adipocyte in insulin resistance: key
molecules and the impact of the
thiazolidinediones.Trends
Endocrinol Metab.2003; 14: 137–145.
69.
Kharroubi I, Lee CH, Hekerman P, Darville MI, Evans RM, Eizirik DL, Cnop M. BCL-6: a possible missing link for
anti-inflammatory PPAR-δsignalling in pancreatic beta cells.Diabetologia.2006;
49: 2350–2358.
70. Ribon V, Printen
JA, Hoffman NG, Kay BK, Saltiel AR. A novel, multifunctional c-Cbl binding
protein in insulin receptor signaling in 3T3-L1 adipocytes.Mol Cell Biol.1998; 18:
872–879.
71. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K, Mori Y, Ide T, Murakami K, Tsuboyama-Kasaoka N, Ezaki O, Akanuma Y, Gavrilova O, Vinson C, Reitman ML, Kagechika H, Shudo K, Yoda M, Nakano Y, Tobe K, Nagai R, Kimura S, Tomita M, Froguel P, Kadowaki T.
The fat-derived hormone adiponectin reverses
insulin resistance associated with both lipoatrophy and obesity.Nature Medicine.2001; 7: 941–946.
72. Watson RT, Kanzaki M, Pessin JE. Regulated membrane
trafficking of the insulin-responsive
glucose transporter 4 in adipocytes.Endocr Rev.2004; 25: 177–204.
73. Monsalve FA, Pyarasani RD, Delgado-LopezF, Moore-Carrasco R. Peroxisome
Proliferator-Activated Receptor Targets for the Treatment of Metabolic Diseases. Mediators Inflamm. 2013;
2013: 549-627.
74. Liang YC, Tsai SH, Tsai DC,
Lin-Shiau SY, Lin JK. Suppression of inducible cyclooxygenase and nitric oxide
synthase through activation of peroxisome proliferator-activated receptor-γby flavonoids in mouse macrophages.FEBS Letters.2001; 496: 12–18.
75.
Kleinsorge H.Carbutamide--the first oral antidiabetic. A
retrospect. Exp Clin Endocrinol
Diabetes. 1998; 106: 149-151.
76. Nolan CJ, Prentki M. The islet beta-cell: fuel responsiveand vulnerable.
Trends Endocrinol Metab 2008; 19: 285-291.
77. Nolan CJ, Madiraju MS,
Delghnngaro-Augusto V, Peyot ML, Prentiki M. Fatty acid
signaling in the beta-cell and insulin secretion. Diabetes 2006; 55 (Suppl 2):
S16-23.
78. Ruiz De Azua I, Gautam D,
Guettier JM, Wess J. Novel
insights into the function of beta-cell M3 muscarinic acetylcholine receptors:
Therapeutic implications. Trends Endocrinol Metab 2011; 22: 74-80.
79. Ashcroft FM, Rorsman P.
Diabetes mellitus and the beta cell: The last ten years. Cell 2012; 148:
1160-1171.
80.
Zou, C.-Y, Gong, Y,
Liang, J. Metabolic signaling
of insulin secretion by pancreatic β-cell and its derangement
in type 2 diabetes. Eur. Rev. Med.
Pharmacol. Sci. 2014;
18: 2215-2227
81. Sekine N, Cirulli V,
Regazzi R, Brown LJ, Gine E, Tamarit-Rodriguez J, Girotti M, Marie S, Macdonald
MJ, Wollheim CB, Rutter GA. Low lactate dehydrogenase and high mitochondrial glycerol phosphate dehydrogenase
in pancreatic beta-cells. Potential role in nutrient sensing. J Biol Chem 1994;
269: 4895-4902.
82.
Kwan EP, Gaisano HY. Rescuing the subprime
meltdown in insulin exocytosis in
diabetes. Ann N Y Acad Sci 2009; 1152: 154-164.
83. Nolan CJ, Damm P, Prentki M.
Type 2 diabetes
across generations: From pathophysiology
to prevention and management. Lancet.
2011; 378: 169-181.
84. Wang Z, Thurmond DC. Mechanisms of biphasic insulin-granule exocytosis— roles of the cytoskeleton, small GTPases and
SNARE proteins. J Cell Sci 2009;
122: 893-903.
85.
Reis AF, Velho G. Sulfonylurea receptor-1 (SUR1):
genetic and metabolic evidences for a role in the susceptibility to Type 2
diabetes mellitus.Diabetes Metab.2002; 28: 14–19
86. Aquilante CL. Sulfonylurea
pharmacogenomics in Type 2 diabetes: the influence of drug target and diabetes
risk polymorphisms. Expert Rev Cardiovasc Ther. 2010; 8: 359–372.
87. Polonsky KS, Given BD, Hirsch LJ, Tillil H, Shapiro ET, Beebe C, Frank BH, Galloway JA, Van Cauter E.
Abnormal patterns of insulin secretion in non-insulin-dependent diabetes
mellitus. N Engl J Med. 1988; 318: 1231–1239.
88. Gromada J, Dissing S, Kofod H, et al. Effects of the
hypoglycaemic drugs repaglinide and glibenclamide on ATP-sensitive
potassium-channels and cytosolic calcium levels in beta TC3 cells and rat
pancreatic beta cells. Diabetologia. 1995; 38: 1025–1032.
89.
Stein, SA Lamos, EM Davis SN. A review of the efficacy and safety of oral antidiabetic drugs. Expert Opin
Drug Saf. 2013; 12: 153–175.
90. Cheng AY, Fantus IG. Oral
antihyperglycemic therapy for type 2 diabetes mellitus. CMAJ. 2005; 172:
213–226.
91.
Gonzalez- Mujica F., Motta
N. Actividad antihiperglicemiante de Bauhinia
megalandra. Vitae. 2010; 43: 1-16.
92. Hu R, Li Y, Lv Q, Wu T, Tong N. Acarbose Monotherapy
and Type 2 Diabetes Prevention in Eastern and Western Prediabetes: An
Ethnicity-specific Meta-analysis. Clin Ther. 2015; 37: 1798-812.
93. Drucker DJ. The
biology of incretin hormones. Cell Metab 2006; 3: 153-165.
94.
Ishii H, Sato Y, Takei M, Nishio S, Komatsu M.
Glucose-incretin interaction revisited.
Endocrine J. 2011; 58:
519-525.
95. Seino S, Takahashi H, Fujimoto W, Shibasaki T (2009)
Roles of cAMP signalling in insulin granule exocytosis. Diabetes Obes Metab 11:
180-188.
96.
LovshinJA,DruckerDJ.Incretin-based
therapies for type 2 diabetes mellitus.Nat Rev Endocrinol. 2009;5: 262–269.
97. UssherJR,DruckerDJ. Cardiovascular
biology of the incretin system.Endocr Rev.2012; 33:187–215.
98. AhmadSR,SwannJ. Exenatide and rare adverse
events.N Engl J Med.2008; 358:
1971–1972.
99. WangQ, BrubakerPL. Glucagon-like
peptide-1 treatment delays the onset of diabetes in 8 week-olddb/dbmice.
Diabetologia.2002; 45:1263–1273.
100.
StoffersDA,
DesaiBM,DeLeonDD, SimmonsRA. Neonatal exendin-4 prevents the development of diabetes
in the intrauterine growth retarded rat.Diabetes. 2003;52:734–740.
101.
DruckerDJ.Incretin-based
therapy and the quest for sustained improvements in β-cell health.Diabetes Care.2011; 34: 2133–2135.
102.
GierB,ButlerPC.Glucagon-like
peptide 1-based drugs and pancreatitis: clarity
at last, but what about pancreatic cancer? JAMA Internal Medicine.2013; 173:539–541.
103.
Mentzel S, Dijkman HB, Van Son JP, Koene RA, Assmann
KJ. Organ distribution of aminopeptidase A and dipeptidyl peptidase IV in
normal mice. J Histochem Cytochem. 1996; 44: 445–461.
104.
Kikuchi M, Fukuyama K, Epstein WL. Soluble
dipeptidyl peptidase IV from terminal differentiated rat epidermal cells:
purification and its activity on synthetic and natural peptides. Arch Biochem
Biophys. 1988; 266: 369–376.
105.
Itou M, Kawaguchi T, Taniguchi E, Sata M. Dipeptidyl peptidase-4: A key player in chronic
liver disease. World J Gastroenterol. 2013; 19: 2298– 2306.
106.
Akter R, Cao P, Noor H, Ridgway Z, Tu L, Wang H, Wong AG, Zhang X, Abedini A, Schmidt AM, Raleigh DP. Islet
Amyloid Polypeptide: Structure, Function,
and Pathophysiology. J. Diabetes Res. 2016; 2016, Article ID 2798269, 18 pages
107.
Nauck
MA. Update on developments with SGLT2 inhibitors in the management of type 2
diabetes. Drug Des Devel Ther. 2014; 8: 1335-1380
108.
Meyer C, Strumvoll M, Madkarni V, Dostou J, Mitrakou
A, Gerich J. Abnormal renal and
hepatic glucose metabolism in type 2 diabetes mellitus. J. Clin. Invest. 1998; 102: 619-624
109.
Grempler
R, Thomas L, Eckhardt M, et al. Empagliflozin, a novel selective sodium glucose cotransporter-2
(SGLT-2) inhibitor: characterisation and comparison
with other SGLT-2 inhibitors. Diabetes Obes Metab. 2012; 14: 83–90.
110.
Staels
B. A review of bile acid sequestrants: potential mechanism(s) for glucose-lowering effects in type 2 diabetes
mellitus.Postgrad Med.2009; 121: 25–30.
111.
Luo
S, Meier AH, Cincotta AH. Bromocriptine reduces obesity, glucose intolerance and extracellular monoamine
metabolite levels in the ventromedial
hypothalamus of Syrian hamsters Neuroendocrinology.
1998; 68: 1–10.